LSD-like panic from risperidone in post-LSD visual disorder

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3, 1996, Pages 238-241

  Abraham, Henry David ^a,b   Mamen, Anitra ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BUTLER HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSERGIDE; NEUROLEPTIC AGENT; RISPERIDONE; SEROTONIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; FEMALE; HALLUCINATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PANIC; PERCEPTION; PRIORITY JOURNAL; VISUAL DISORDER;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HALLUCINATIONS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MALE; PANIC DISORDER; RISPERIDONE;

EID: 0029892811     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606000-00008     Document Type: Article

References (26)

1. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 1994;55:5-12.
2. Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. Psychopharmacology 1989;99:445-9.
3. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-8.
4. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
5. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992;41:494-508.
6. Owens DG. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55:29-35.
7. Sandison RA, Spencer AM, Whitelaw JD. The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 1954;100:491-502.
8. Eisner BG, Cohen S. Psychotherapy with lysergic acid diethylamide. J Nerv Ment Dis 1958;127:528-39.
9. Rosenthal SH. Persistent hallucinosis following repeated administration of hallucinogenic drugs. Am J Psychiatry 1964;121:238-44.
10. Robbins E, Frosch WA, Stern M. Further observations on untoward reactions to LSD. Am J Psychiatry 1967;124:393-5.
11. Holsten F. Flashbacks: a personal follow-up. Arch Psychiatr Nervenkr 1976;222:293-304.
12. Horowitz MJ. Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 1969;126:565-9.
13. Shick JFE, Smith D. Analysis of the LSD flashback. J Psychedel Drugs 1970;3:13-9.
14. Anderson W, O'Malley J. Trifluoperazine for the trailing phenomenon. JAMA 1972;220:1244-5.
15. Abraham HD. Visual disturbances in a population of LSD users. 143th Annual Meeting of the American Psychiatric Association. New Orleans, 1981.
16. Abraham HD. A chronic impairment of color vision in users of LSD. Br J Psychiatry 1982;140:518-20.
17. Abraham HD. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983;40:884-9.
18. Abraham HD, Wolf E. Visual function in past users of LSD: psychophysical findings. J Abnorm Psychol 1988;97:443-7.
19. Abraham HD, Duffy FH, Crayton J, Yeoh H. The diagnosis and treatment of chronic visual disturbances following LSD. 148th Annual Meeting of the American Psychiatric Association. Miami, 1995.
20. Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993;88:1327-34.
21. Glennon RA, Titeler M, McKenney JD. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci 1984;35:2505-11.
22. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, Ecker JA, Faludi G. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994;55:234-41.
23. Pazos A, Cortõs R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985;346:231-49.
24. Morilak DA, Garlow SJ, Ciaranello RD. Immunocytochemical localization and description of neurons expressing serotonin2 receptors in the rat brain. Neuroscience 1993;54:701-17.
25. Sheldon PW, Aghajanian GK. Serotonin (5-HT) induces IPSPs in pyramidal layer cells of rat piriform cortex: evidence for the involvement of a 5-HT2-activated interneuron. Brain Res 1990;506:62-9.
26. Garratt JC, Alreja M, Aghajanian GK. LSD has high efficacy relative to serotonin in enhancing the cationic current-Ih: intracellular studies in rat facial motoneurons. Synapse 1993;13:123-34.